Berlex ABOVE Study Will Evaluate Switching Avonex MS Patients To Betaseron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex/Chiron’s ABOVE (Interferon beta-1a vs. Interferon beta-1b Observation of Efficacy) study will evaluate whether there is a benefit to switching relapsing-remitting MS patients from once-weekly treatment with Biogen’s Avonex to Berlex’ more frequently administered and higher-dose Betaseron.